Purkinje peak

The ancillary peaks related to the Bezold-Brucke and the Purkinje Effects are particularly relevant to determining the precise amount of crossover between the spectral absorption characteristics. A putative peak near 390 nm in the aphakic human eye would also be very useful in evaluating these parameters. See Section 17.2.4. 

Fig. 6. Summary histogram of development of glutamate receptors at parallel [postnatal day 10 (PI0) to adult] and climbing (P2 to adult) fiber synapses on Purkinje cells of the cerebellum. Note especially the peak in immunogold labeling of the delta receptors at PI0-PI4 in climbing fiber synapses (cO, the peaks of the AMPA receptors (GluR2, GluR2/3 antibodies) at P2-P5, and the inverse patterns of peaks for parallel fiber synapses (pf) and climbing fiber synapses in adults for AMPA versus delta receptors. Modified from Zhao et al. (1998).

Encainide, a class 1C antiarrhythmic agent, is available on a limited basis only to patients with life-threatening ventricular arrhythmias. Encainide slows conduction velocity, inhibits automaticity, and increases the ratio of the effective refractory period to action potential duration. It blocks the sodium channel of Purkinje fibers and the myocardium. Encainide is absorbed well, reaches peak plasma level in 30 to 90 minutes, becomes metabolized to 0-demethyl encainide (ODE) and 3-methoxy-O-demethyl encainide (MODE), which are active antiarrhythmic agents, and the metabolites are excreted by the kidneys. In renal impairment, the clearance of ODE and MODE is decreased, and hence the dosage should be reduced. Encainide may either worsen or create new arrhythmias, especially in electrolyte-imbalanced patients. Encainide is known to have caused sinus bradycardia, sinus pause, or sinus arrest (see also Eigure 84). 

---